Supernus Pharmaceuticals, Inc.
Key Metrics
- Previous Close
- $29.04
- 52-Week Range
- $25.92 – $42.81
- Market Cap
- $6.02B
- P/E (TTM)
- —
- EPS (TTM)
- -0.76
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- —
- PEG Ratio
- —
- Return on Equity
- —
- Return on Assets
- 29.34%
- Gross Margin
- 85.73%
- Operating Margin
- 46.94%
- Profit Margin
- 32.75%
- Current Ratio
- 0.61
- Debt/Equity
- —
- Total Debt
- $501.00M
- Free Cash Flow
- $227.12M
- Revenue Growth
- 13.40%
- Earnings Growth
- 239.40%
- Enterprise Value
- $3.61B
Market Snapshot
About
Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The company markets FDA-approved medications for epilepsy, ADHD, and other neurological conditions. Supernus has a pipeline of additional product candidates in various stages of clinical development.